Advertisement
Among China's millions of public and private enterprises, approximately800 companies from a variety of industries have been selected to join the IPpilot program. As a high growth company with a focus on technology innovationand intellectual property, Renhuang was selected as one of a handful ofpharmaceutical companies from Heilongjiang province to enroll in the pilotprogram. As a participant of the IP pilot program, the Company will receiveguidance from the SIPO in creating, using, protecting and managingintellectual property to foster innovation while protecting proprietarytrademarks, technologies, processes, and products. The primary goal of thetwo-year IP pilot program is to help improve China's economic growth andinternational competitiveness by strengthening its patent and trademark system.
Advertisement
"The selection process for the IP pilot program was competitive and we arepleased to be a part of this unique opportunity. Our business thrives oninnovation and strong intellectual property protection is a core component ofour long-term success, including maintaining our leadership in the SiberianGinseng (Acanpathax) based product market," said Mr. Shaoming Li, Chairman andChief Executive Officer of Renhuang. "Over the years, Renhuang has takenimportant steps to develop and manage our intellectual property portfolio. Weplan to capitalize on the vast opportunities provided by this pilot program tocontinue to expand our intellectual property to further strengthen ourcompetitive position."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development,manufacturing, and distribution of botanical products, bio-pharmaceuticalproducts, and traditional Chinese medicines ("TCM"), in the People's Republicof China. All of the Company's products are produced at its threeGMP-certified production facilities in Ah City, Dongfanghong and Qingyang.The Company distributes its botanical anti-depression and nerve-regulationproducts, biopharmaceutical products, and botanical antibiotic and OTC TCMsthrough its network of over 3,000 distributors and over 70 sales centersacross 24 provinces in China. Company Website: http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may includeforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are based upon management'sbeliefs, assumptions and expectations of the Company's future operations andeconomic performance, taking into account the information currently availableto management. These statements are not statements of historical fact.Forward-looking statements involve risks and uncertainties, some of which arenot currently known that may cause actual results, performance or financialcondition to be materially different from the expectations of future results,performance or financial condition expressed or implied in any forward-lookingstatements. These forward-looking statements are based on current plans andexpectations and are subject to a number of uncertainties including, but notlimited to, the Company's participation in the intellectual property pilotprogram, ability to build and maintain intellectual property protection aroundkey assets, ability to manage expansion of its operations effectively, andother factors detailed in the Company's annual report on Form 10-K and otherfilings with the Securities and Exchange Commission. The Company undertakesno obligation to publicly update or revise any forward-looking statements,whether as a result of new information, future events or otherwise. You arecautioned not to unduly rely on such forward-looking statements whenevaluating the information presented herein.For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: [email protected] CCG Investor Relations: Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: [email protected] Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected]
SOURCE Renhuang Pharmaceuticals, Inc.
